![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/342726-501926932-logo-nextcure-jpg-100x17.jpeg)
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-end NC410 combo with pembrolizumab ovarian cohort enrollment completed Cash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE …